Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Fred Aslan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 115
- Beta
- 2.41
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 7.58
Financials
Revenue
$0.00-100.0%Net Income
$-25.00MEBITDA
$-23.65MFree Cash Flow
$-41.96MEPS (diluted)
$-0.63Shares Outstanding (diluted)
39.41M+124.2%Operating Expenses
$26.89MCash & Debt
$349.39MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-83.86M | $-3.43 |
| 2024 | $251.0K | $-58.49M | $-5.20 |
| 2023 | $33.49M | $-27.70M | $-1.19 |
| 2022 | $4.93M | $-58.39M | $-3.32 |
| 2021 | $2.00M | $-71.83M | $-4.08 |
| 2020 | $0.00 | $-17.99M | $-1.02 |
Valuation
ARTVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·17d ago·Neutral
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026) Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
View source ↗ - Newsglobenewswire.com·25d ago·Negative
…of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren's Disease (ISSjD 2026…
View source ↗ - Newsglobenewswire.com·40d ago·Negative
… on site activation and enrollment initiation expected in the second half of 2026 SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today provided an update on anticipated data disclosures and development milestones for its lead program, AlloNK® (also known as AB-101), through year-en…
View source ↗ - Newsglobenewswire.com·46d ago·Negative
…tiva Biotherapeutics to Participate in Upcoming Investor Conferences in September SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on …
View source ↗
Earnings
Wed, Nov 11(in 3 weeks)
Consensus estimate $-0.54 per share
Typical surprise -0.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.63 vs $-0.63miss
- Fri, May 8$-0.95 vs $-0.88miss
- Tue, Mar 10$-0.84 vs $-0.87beat
- Wed, Nov 12$-0.88 vs $-0.92beat
- Wed, Aug 6$-0.87 vs $-0.84miss
- Thu, May 8$-0.83 vs $-0.68miss
Estimates and results for ARTV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARTV officers and directors.
- Bought
- $109.2m
- Sold
- $2.5m
23 trades
18 trades
- Aslan Fredsold
- Horan Christophersold
- Bush Jennifersold
- Banerjee Subhashissold
- Aslan Fredsold
- Aslan Fredsold
- Horan Christophersold
- Bush Jennifersold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARTV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.